REDWOOD CITY, Calif., Dec. 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). AcelRx's addition to the NBI will become effective prior to market open on Monday, December 24, 2018.
The NASDAQ Biotechnology Index (NBI) contains securities of NASDAQ-listed companies that meet certain eligibility criteria, and are classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. These requirements include minimum market capitalization, and average daily trading volume. The index is re-ranked annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.
For more information about the NBI visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-added-to-the-nasdaq-biotechnology-index-nbi-300767895.html
SOURCE AcelRx Pharmaceuticals, Inc.
Theresa Dolge, Evoke, 215-928-2748, firstname.lastname@example.org; Jessica Ross, Evoke, 215-928-2346, email@example.com; Investor Contacts: Raffi Asadorian, CFO, AcelRx, firstname.lastname@example.org; Brian Korb, Solebury Trout, 646-378-2923, email@example.com